| Literature DB >> 33082781 |
Georgios Tziatzios1, Dimitrios N Samonakis2, Theocharis Tsionis3, Spyridon Goulas4, Dimitrios Christodoulou5, Konstantinos Triantafyllou1.
Abstract
OBJECTIVES: To examine the impact of endoscopy setting (hospital-based vs. office-based) on sedation/analgesia administration and to provide nationwide data on monitoring practices among Greek gastroenterologists in real-world settings. Material and Methods. A web-based survey regarding sedation/analgesia rates and monitoring practices during endoscopy either in a hospital-based or in an office-based setting was disseminated to the members of the Hellenic Society of Gastroenterology and Professional Association of Gastroenterologists. Participants were asked to complete a questionnaire, which consisted of 35 items, stratified into 4 sections: demographics, preprocedure (informed consent, initial patient evaluation), intraprocedure (monitoring practices, sedative agents' administration rate), and postprocedure practices (recovery).Entities:
Year: 2020 PMID: 33082781 PMCID: PMC7556063 DOI: 10.1155/2020/8701791
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Figure 1Geographical distribution of participants.
Figure 2Participants' workload by endoscopic procedure. Data are expressed as percentage according to predefined ranges (0%, 1-25% of procedures, between 26 and 50%, between 51 and 75%, and over 75%). EGD: esophagogastroduodenoscopy; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound; ESD: endoscopic submucosal dissection; POEM: per oral endoscopic myotomy.
Figure 3Participants' workload by setting (private office, clinic in private hospital, and clinic in public hospital). Data are expressed as percentage according to predefined ranges (0%, 1-25% of procedures, between 26 and 50%, between 51 and 75%, and over 75%).
Survey responses.
| Question |
| |
|---|---|---|
|
| ||
|
| ||
| Informed consent before the endoscopic procedure ( | I inform in writing about the possible complications in detail, and I get written consent from all patients | 96 (45.5) |
| I do not receive written informed consent, but I inform about possible complications in detail, and I get oral consent from all patients | 47 (22.3) | |
| I do not receive written informed consent, but I do inform about possible complications in detail, and I receive oral consent from patients undergoing diagnostic procedures | 42 (19.9) | |
| I inform in writing about the possible complications in detail, and I get written consent only in high-risk procedures | 21 (10.0) | |
| I inform in writing about the possible complications, and I get written consent from all patients for endoscopy without sedation | 4 (1.9) | |
| I inform in detail, and I get written consent for the possibility of endoscopy without sedation | 1 (0.5) | |
|
| ||
| Endoscopist administering intravenous sedation is familiar with ( | Airway management techniques | 183 (86.7) |
| Oropharyngeal airway management | 138 (65.4) | |
| Bag valve mask- (BVM-) Ambu use | 177 (83.9) | |
| Endotracheal intubation | 49 (23.2) | |
| Basic Life Support (BLS) | 105 (49.7) | |
| Advanced Life Support (ALS) | 46 (21.8) | |
| Immediate Life Support (ILS) | 113 (53.6) | |
|
| ||
| During initial assessment of the patient, endoscopist is familiar with ( | Sedation/anesthesia levels | 94 (44.5) |
| ASA physical status classification system and sedation/anesthesia levels | 53 (25.1) | |
| All the above | 26 (12.3) | |
| American Society of Anesthesiologists (ASA) physical status classification system | 22 (10.4) | |
| The Mallampati score to predict difficult intubation | 8 (3.8) | |
| The Mallampati score and sedation/anesthesia levels | 6 (2.8) | |
| ASA physical status classification system and the Mallampati score | 2 (0.9) | |
|
| ||
|
| ||
|
| ||
| Monitoring of patient during examination by ( | SaO2 and pulse monitoring | 211 (100.0) |
|
| 108 (51.1) | |
| Electrocardiogram monitoring | 44 (20.9) | |
| Capnography monitoring | 16 (7.6) | |
|
| ||
| Who is the sedation administrator during endoscopy? ( | At the private office, the endoscopist | 59 (28.0) |
| At the private office, the anesthesiologist | 5 (2.4) | |
| At the private clinic, the endoscopist | 47 (22.3) | |
| At the private clinic, the anesthesiologist | 31 (14.7) | |
| At the public hospital, the endoscopist | 63 (29.9) | |
| At the public hospital, the anesthesiologist | 6 (2.8) | |
|
| ||
|
| ||
|
| ||
| Patient's resuscitation is performed ( | Under supervision of the nursing personnel, in most cases | 99 (46.9) |
| Under supervision of the endoscopist, in most cases | 92 (43.6) | |
| Under supervision of the anesthesiologist, in most cases | 20 (9.5) | |
|
| ||
| Separate resuscitation room | Private office ( | 51 (35.2) |
| Private clinic ( | 82 (80.4) | |
| Public clinic ( | 54 (58.7) | |
n: number of responses received for each question. ∗Sum is greater than 100% due to multiple possible answers for the question.
Comparison of sedative/analgesic agents' use between private office and hospital-based (private and public) settings.
| 0% | 1–25% | 26–50% | 51–75% | >75% |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Office setting | Hospital setting | Office setting | Hospital setting | Office setting | Hospital setting | Office setting | Hospital setting | Office setting | Hospital setting | ||
|
| |||||||||||
|
| |||||||||||
| Midazolam | 0% | 5.6% | 7.1% | 2.5% | 5.8% | 4.3% | 2.9% | 5.6% | 84.2% | 82.0% |
|
| Pethidine | 95.5% | 78.7% | 1.5% | 12.3% | 0% | 1.9% | 0% | 1.9% | 3.0% | 5.2% |
|
| Fentanyl | 67.6% | 69.4% | 1.5% | 7.0% | 1.5% | 2.5% | 1.4% | 7.6% | 28.0% | 13.4% |
|
| Propofol | 88.4% | 34.1% | 1.6% | 9.8% | 1.4% | 7.3% | 1.4% | 2.4% | 7.2% | 46.3% |
|
|
| |||||||||||
|
| |||||||||||
| Midazolam | 7.1% | 6.2% | 0% | 0% | 1.4% | 3.7% | 1.4% | 2.5% | 90.1% | 87.7% |
|
| Pethidine | 89.9% | 66.5% | 4.4% | 9.7% | 1.4% | 9.0% | 0% | 0.6% | 4.3% | 14.2% |
|
| Fentanyl | 52.9% | 46.9% | 4.4% | 13.8% | 0% | 6.3% | 2.9% | 4.4% | 39.8% | 28.7% |
|
| Propofol | 83.8% | 31.5% | 4.4% | 9.9% | 3.0% | 8.6% | 0% | 4.9% | 8.8% | 45.1% |
|
EGD: esophagogastroduodenoscopy.
Comparison of sedative/analgesic agents' use between private office and hospital-based (private and public) settings when workload > 75%.
| Medication | Private clinic | Public clinic |
| Private office |
|
|---|---|---|---|---|---|
|
| |||||
|
| |||||
| Midazolam | 78.7% | 89.1% |
| 87.3% |
|
| Pethidine | 6.2% | 12.4% |
| 2.3% |
|
| Fentanyl | 25.2% | 18.5% |
| 25.7% |
|
| Propofol | 85.8% | 19.5% |
| 10.5% |
|
|
| |||||
|
| |||||
|
| |||||
| Midazolam | 81.1% | 93.9% |
| 87.5% |
|
| Pethidine | 8.2% | 24.9% |
| 6.2% |
|
| Fentanyl | 31.6% | 32.2% |
| 40.1% |
|
| Propofol | 88.2% | 20.1% |
| 9.4% |
|
∗ p value referring to the comparison between private and public clinic. ∗∗p value referring to the comparison between private clinic and private office. EGD: esophagogastroduodenoscopy.
Figure 4Sedation administration of (a) endoscopist and (b) anesthesiologist, by setting (clinic in private hospital, clinic in public hospital, and private office). ns: not significant; ∗p < 0.05.